share_log

默沙东已完成对同润生物医药B细胞耗竭疗法在研药物CN201的收购

Gelonghui Finance ·  Oct 1 07:09

格隆汇10月1日|默沙东宣布,公司已完成对同润生物医药CN201的资产收购。CN201是用于治疗B细胞相关疾病的新型在研临床阶段双特异性抗体。

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment